China Traditional Chinese Medicine Holdings Co. Limited has announced its unaudited consolidated results for the six months ended 30 June 2025. The company reported a total revenue of RMB 7.46 billion, a decline of 11.0% compared to RMB 8.39 billion in the same period of the previous year. The revenue from concentrated Traditional Chinese Medicines (TCM) granules decreased by 14.1% to RMB 2.99 billion. TCM finished drugs saw a 4.5% decrease in revenue, amounting to RMB 2.31 billion. TCM decoction pieces experienced a slight growth of 1.2%, reaching RMB 1.60 billion. The Chinese medicinal herbs integration business recorded a significant drop in revenue by 40.9% to RMB 445.58 million, while the TCM great health segment saw a decline of 21.8%, totaling RMB 122.11 million. The gross profit for the period was RMB 3.63 billion, marking a 10.5% decrease from RMB 4.06 billion in the corresponding period of 2024. There was no reported information on net income or profit/loss figures in the announcement. The results reflect the company's diverse customer base, with no single customer accounting for more than 10% of the group's revenue in either the current or previous reporting periods. There is no outlook or guidance provided in the current announcement.